# Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

> **NCT00737282** · PHASE3 · TERMINATED · sponsor: **Repros Therapeutics Inc.** · enrollment: 175 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** Proellex 25 mg
- **DRUG:** Proellex 50 mg

## Key facts

- **NCT ID:** NCT00737282
- **Lead sponsor:** Repros Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 175 (ACTUAL)
- **Why stopped:** Repros stopped study for safety and FDA put study on hold.
- **Last updated:** 2014-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00737282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00737282, "Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00737282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*